# Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

> **NCT00001761** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 15 (—)

## Conditions studied

- Vasculitis
- Wegener's Granulomatosis

## Interventions

- **DRUG:** Interleukin-10

## Key facts

- **NCT ID:** NCT00001761
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-02
- **Primary completion:** —
- **Final completion:** 2000-04
- **Target enrollment:** 15 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001761, "Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00001761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*